MeiraGTx Holdings plc (MGTX)
$9.94-4.24%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $921M
- Beta
- 1.35
- P/E (TTM)
- 13.08
- Short % float
- 8.55%
- Days to cover
- 5.0
- SI change
- +49.5%
- 1W
- -6.23%
- 1M
- -22.83%
- vs SPY 1W
- -6.09%
- vs SPY 1M
- -25.33%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 37
- VALUE
- 30
- GROWTH
- 71
- GARP
- 14
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC170.6%
REV YoY-
ROE284.4%
EPS YoY-
ROA19.9%
GROSS97
OP46
NET20
[VALUATION]
P/E TTM13.08
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B4.22
P/FCF-
EV/EBITDA3.39
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E52.10
ALTMAN Z-
CURR RATIO3.76
ND/EBITDA-
BETA1.35
Company news
FAQ
- What is LOPJLB’s current signal on MGTX?
- LOPJLB’s latest quantitative signal on MeiraGTx Holdings plc (MGTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MGTX in?
- MeiraGTx Holdings plc (MGTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MeiraGTx Holdings plc (MGTX) do?
- MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The c…